melatonin has been researched along with Nervous System Disorders in 40 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin can be considered as a promising solution in preventing neuroinflammation development in T2DM owing to its ability to render the oxidative stress and accompanied low-grade systemic inflammation." | 7.96 | Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression. ( Elguindy, NM; Hashem, HM; Maher, AM; Saleh, SR; Yacout, GA, 2020) |
| "Clonazepam has been considered the treatment of choice for RBD." | 5.32 | Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. ( Boeve, BF; Ferman, TJ; Silber, MH, 2003) |
| " Melatonin, a biologically active substance, acts as a pleiotropic hormone essential for pregnancy and fetal development." | 5.01 | Perinatal Use of Melatonin for Offspring Health: Focus on Cardiovascular and Neurological Diseases. ( Hsu, CN; Huang, LT; Tain, YL, 2019) |
| " This article focuses on the following specific neurologic diseases: nocturnal frontal lobe epilepsy and abnormal motor behaviors of epileptic origin, evaluating differential diagnosis with parasomnias; achondroplasia, confirming the crucial role of craniofacial deformity in determining sleep-disordered breathing; neuromuscular diseases, mainly Duchenne's muscular dystrophy and myotonic dystrophy; cerebral palsy, evaluating either the features of sleep architecture and the importance of the respiratory problems associated; headaches, confirming the strict relationships with sleep in terms of neurochemical and neurobehavioral substrates; and finally a review on the effectiveness of melatonin for sleep problems in children with neurologic syndromes and mental retardation, blindness, and epilepsy." | 4.81 | Sleep disorders in children with neurologic diseases. ( Bruni, O; Zucconi, M, 2001) |
| "Melatonin can be considered as a promising solution in preventing neuroinflammation development in T2DM owing to its ability to render the oxidative stress and accompanied low-grade systemic inflammation." | 3.96 | Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression. ( Elguindy, NM; Hashem, HM; Maher, AM; Saleh, SR; Yacout, GA, 2020) |
| "Melatonin is a neuroregulator hormone that has free radical scavenger, strong antioxidant, anti-inflammatory, and immunosuppressive actions." | 2.66 | Melatonin: A review of its potential functions and effects on neurological diseases. ( Acet, HA; Gunata, M; Parlakpinar, H, 2020) |
| "Melatonin is a neurohormone secreted from the pineal gland and has a wide-ranging regulatory and neuroprotective role." | 2.58 | The neuroprotective role of melatonin in neurological disorders. ( Alghamdi, BS, 2018) |
| "Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases." | 2.55 | Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. ( Martinez-Cue, C; Mediavilla, MD; Reiter, RJ; Rueda, N; Sanchez-Barcelo, EJ, 2017) |
| "Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care." | 2.46 | Clinical uses of melatonin: evaluation of human trials. ( Mediavilla, MD; Reiter, RJ; Sánchez-Barceló, EJ; Tan, DX, 2010) |
| "Melatonin has been shown to either stimulate gene expression for the antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase) or to increase their activity." | 2.42 | Neuroprotective role of melatonin in oxidative stress vulnerable brain. ( Gupta, M; Gupta, YK; Kohli, K, 2003) |
| "Many neurological disorders are associated with abnormal 24-hour rhythms, including the sleep-wake cycle." | 2.41 | Current understanding of the circadian clock and the clinical implications for neurological disorders. ( Dugovic, C; Turek, FW; Zee, PC, 2001) |
| "Melatonin is a drug widely used, particularly for electroencephalogram in children." | 1.43 | Efficiency of Melatonin as Compared to Pentobarbital for Audiometry Brainstem Response in Children With Associated Disorders. ( Garabedian, EN; Guerlain, J; Loundon, N; Parodi, M; Paul, A; Rouillon, I, 2016) |
| "Treatment with melatonin derivatives 4, 6, 7 and 11 (i." | 1.36 | Potent neuroprotective role of novel melatonin derivatives for management of central neuropathy induced by acrylamide in rats. ( Abd-Elhalim, MM; Ahmed, HH; el-Sayed, el-SM; Elmegeed, GA; Shafic, RW; Shousha, WG, 2010) |
| "Melatonin has efficient protective effects against various oxidative damages in nervous system." | 1.36 | Melatonin protects against Nickel-induced neurotoxicity in vitro by reducing oxidative stress and maintaining mitochondrial function. ( He, MD; Wang, Y; Xu, SC; Yang, J; Yang, L; Yu, ZP; Zhang, YW; Zhong, M; Zhou, Z, 2010) |
| " Theophylline, a re-emerging drug for the treatment of obstructive airway disease, has a narrow therapeutic index which precludes its safe use." | 1.34 | Free radicals and theophylline neurotoxicity : an experimental study. ( Gulati, K; Ray, A; Vijayan, VK, 2007) |
| "Clonazepam has been considered the treatment of choice for RBD." | 1.32 | Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. ( Boeve, BF; Ferman, TJ; Silber, MH, 2003) |
| "When melatonin was injected intraperitoneally at a single dose of 5 mg/kg 10 min before KA administration, it significantly reduced these pathological neurobehavioral changes and almost completely attenuated the increase in LPO and morphological damage induced by KA." | 1.30 | Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice. ( El-Sokkary, GH; Kim, SJ; Manchester, LC; Qi, W; Reiter, RJ; Tan, DX, 1998) |
| "Melatonin assay has proved to be clinically useful for the diagnosis and investigation of several diseases (e." | 1.28 | Measurement of melatonin in blood by radioimmunoassay. Analytical considerations and clinical usefulness. ( Burlina, A; Burlina, AP; Chiozza, ML; Masiero, M; Plebani, M; Scanarini, M, 1990) |
| "Two patients with sympathotonic orthostatic hypotension excreted greater amounts of 6-hydroxymelatonin than any of the control subjects." | 1.26 | Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension. ( Kopin, IJ; Markey, SP; Polinsky, RJ; Tetsuo, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 8 (20.00) | 18.2507 |
| 2000's | 13 (32.50) | 29.6817 |
| 2010's | 12 (30.00) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, HH | 1 |
| Elmegeed, GA | 1 |
| el-Sayed, el-SM | 1 |
| Abd-Elhalim, MM | 1 |
| Shousha, WG | 1 |
| Shafic, RW | 1 |
| Tan, HY | 1 |
| Ng, KY | 1 |
| Koh, RY | 1 |
| Chye, SM | 1 |
| Gunata, M | 1 |
| Parlakpinar, H | 1 |
| Acet, HA | 1 |
| Hsu, CN | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Maher, AM | 1 |
| Saleh, SR | 1 |
| Elguindy, NM | 1 |
| Hashem, HM | 1 |
| Yacout, GA | 1 |
| Reiter, RJ | 4 |
| Rosales-Corral, S | 1 |
| Sharma, R | 1 |
| Leung, JW | 1 |
| Cheung, KK | 1 |
| Ngai, SP | 1 |
| Tsang, HW | 1 |
| Lau, BW | 1 |
| Sanchez-Barcelo, EJ | 2 |
| Rueda, N | 1 |
| Mediavilla, MD | 2 |
| Martinez-Cue, C | 1 |
| Zisapel, N | 1 |
| Alghamdi, BS | 1 |
| Beresford, B | 1 |
| McDaid, C | 1 |
| Parker, A | 1 |
| Scantlebury, A | 1 |
| Spiers, G | 1 |
| Fairhurst, C | 1 |
| Hewitt, C | 1 |
| Wright, K | 1 |
| Dawson, V | 1 |
| Elphick, H | 1 |
| Thomas, M | 1 |
| Stanford, SC | 1 |
| Guerlain, J | 1 |
| Paul, A | 1 |
| Rouillon, I | 1 |
| Parodi, M | 1 |
| Garabedian, EN | 1 |
| Loundon, N | 1 |
| Fu, J | 1 |
| Xia, X | 1 |
| Liu, Z | 1 |
| Wang, Y | 3 |
| Shi, Q | 1 |
| Song, X | 1 |
| Song, E | 1 |
| Song, Y | 1 |
| Tan, DX | 2 |
| Xu, SC | 1 |
| He, MD | 1 |
| Zhong, M | 1 |
| Zhang, YW | 1 |
| Yang, L | 1 |
| Yang, J | 1 |
| Yu, ZP | 1 |
| Zhou, Z | 1 |
| Uchida, K | 1 |
| Tateda, T | 1 |
| Hino, H | 1 |
| Boeve, BF | 1 |
| Silber, MH | 1 |
| Ferman, TJ | 1 |
| Bertsche, T | 1 |
| Schulz, M | 1 |
| Gupta, YK | 1 |
| Gupta, M | 1 |
| Kohli, K | 1 |
| De Leersnyder, H | 2 |
| Claustrat, B | 2 |
| Munnich, A | 1 |
| Verloes, A | 1 |
| Altun, A | 1 |
| Ugur-Altun, B | 1 |
| Gulati, K | 1 |
| Ray, A | 1 |
| Vijayan, VK | 1 |
| Tetsuo, M | 1 |
| Polinsky, RJ | 1 |
| Markey, SP | 2 |
| Kopin, IJ | 1 |
| Evtushenko, SK | 2 |
| Spector, NH | 1 |
| Manev, H | 1 |
| Uz, T | 1 |
| Wurtman, RJ | 1 |
| Zhdanova, II | 1 |
| Manchester, LC | 1 |
| Qi, W | 1 |
| Kim, SJ | 1 |
| El-Sokkary, GH | 1 |
| Khavinson, V | 1 |
| Goncharova, N | 1 |
| Lapin, B | 1 |
| Turek, FW | 1 |
| Dugovic, C | 1 |
| Zee, PC | 1 |
| Zucconi, M | 1 |
| Bruni, O | 1 |
| Ross, C | 1 |
| Davies, P | 1 |
| Whitehouse, W | 1 |
| Rudman, D | 1 |
| O'Brien, MS | 1 |
| McKinney, AS | 1 |
| Hoffman, JC | 1 |
| Patterson, JH | 1 |
| Boni, RL | 1 |
| Yergey, JA | 1 |
| Heyes, MP | 1 |
| Svechkin, OV | 1 |
| Samsonenko, RA | 1 |
| Plebani, M | 1 |
| Masiero, M | 1 |
| Burlina, AP | 1 |
| Chiozza, ML | 1 |
| Scanarini, M | 1 |
| Burlina, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| Stellate Ganglion Block in Patients With Advanced Primary Parkinson's Disease: a Small, Open, Randomized, Controlled Clinical Study[NCT06112392] | 38 participants (Anticipated) | Interventional | 2023-07-28 | Recruiting | |||
| Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study[NCT02836743] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study[NCT00745030] | 3 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Low subject recruitment and enrollment.) | |||
| A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)[NCT05922995] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for melatonin and Nervous System Disorders
| Article | Year |
|---|---|
Pharmacological Effects of Melatonin as Neuroprotectant in Rodent Model: A Review on the Current Biological Evidence.
Topics: Animals; Apoptosis; Disease Models, Animal; Melatonin; Nervous System Diseases; Neuroprotective Agen | 2020 |
Melatonin: A review of its potential functions and effects on neurological diseases.
Topics: Aging; Animals; History, 20th Century; History, 21st Century; Humans; Melatonin; Nervous System Dise | 2020 |
Perinatal Use of Melatonin for Offspring Health: Focus on Cardiovascular and Neurological Diseases.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Female; Fetal Development; Fetal Diseases; Humans; I | 2019 |
Circadian disruption, melatonin rhythm perturbations and their contributions to chaotic physiology.
Topics: Animals; Circadian Rhythm; Humans; Melatonin; Nervous System Diseases; Pineal Gland; Stress, Psychol | 2020 |
Protective Effects of Melatonin on Neurogenesis Impairment in Neurological Disorders and Its Relevant Molecular Mechanisms.
Topics: Aging; Animals; Humans; Melatonin; Nervous System Diseases; Neurogenesis; Oxidative Stress; Protecti | 2020 |
Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.
Topics: Animals; Clinical Trials as Topic; Humans; Melatonin; Mental Disorders; Nervous System Diseases; Oxi | 2017 |
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation.
Topics: Animals; Cardiovascular Diseases; Circadian Rhythm; Humans; Melatonin; Nervous System Diseases; Slee | 2018 |
The neuroprotective role of melatonin in neurological disorders.
Topics: Animals; Humans; Melatonin; Nervous System Diseases; Neuroprotection; Neuroprotective Agents | 2018 |
Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Complementary Therapies; Data Accurac | 2018 |
Clinical uses of melatonin: evaluation of human trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Communicable Diseases; Endocrine System Diseases; | 2010 |
[Melatonin. A clinical-pharmacological assessment].
Topics: Aged; Animals; Antioxidants; Dietary Supplements; Drug Interactions; Humans; Melatonin; Mental Disor | 2004 |
Neuroprotective role of melatonin in oxidative stress vulnerable brain.
Topics: Animals; Antioxidants; Brain; Humans; Melatonin; Nervous System Diseases; Neuroprotective Agents; Ox | 2003 |
[Disruptions of circadian rhythm in neurologic disorders].
Topics: Autonomic Nervous System Diseases; Body Temperature Regulation; Brain Neoplasms; Central Nervous Sys | 2006 |
Melatonin: therapeutic and clinical utilization.
Topics: Cardiovascular Diseases; Circadian Rhythm; Humans; Immune System; Immune System Diseases; Jet Lag Sy | 2007 |
[Melatonin and its role in experimental and clinical neuroimmunology].
Topics: Animals; Humans; Melatonin; Nervous System Diseases; Neuroimmunomodulation; Neurosecretory Systems; | 1994 |
Science and hyperbole: melatonin.
Topics: Animals; Health Education; Humans; Mass Media; Melatonin; Nervous System Diseases; Neurosciences | 1997 |
Current understanding of the circadian clock and the clinical implications for neurological disorders.
Topics: Animals; Biological Clocks; Circadian Rhythm; Humans; Melatonin; Nervous System Diseases; Neurons; S | 2001 |
Sleep disorders in children with neurologic diseases.
Topics: Anticonvulsants; Blindness; Child; Child, Preschool; Diagnosis, Differential; Epilepsy; Headache; Hu | 2001 |
[Melatonin treatment of sleep disorders in children].
Topics: Antioxidants; Child; Child Welfare; Circadian Rhythm; Drug Administration Schedule; Humans; Melatoni | 2002 |
Mass spectrometric determinations of tryptophan and its metabolites.
Topics: Animals; Body Fluids; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Melatonin; Mo | 1991 |
1 trial available for melatonin and Nervous System Disorders
| Article | Year |
|---|---|
Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: an observational study.
Topics: Adolescent; Child; Child, Preschool; Developmental Disabilities; Dose-Response Relationship, Drug; E | 2002 |
19 other studies available for melatonin and Nervous System Disorders
| Article | Year |
|---|---|
Potent neuroprotective role of novel melatonin derivatives for management of central neuropathy induced by acrylamide in rats.
Topics: Acrylamide; Animals; Antioxidants; Brain; Female; L-Lactate Dehydrogenase; Magnetic Resonance Spectr | 2010 |
Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2,3-dioxygenase 1 expression.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Antioxidants; Cytokines; Diabetes Mellitus, | 2020 |
Recent developments in research of melatonin and its potential therapeutic applications.
Topics: Animals; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Neoplasms; Nervous System Diseases; | 2018 |
Efficiency of Melatonin as Compared to Pentobarbital for Audiometry Brainstem Response in Children With Associated Disorders.
Topics: Adolescent; Audiometry, Evoked Response; Central Nervous System Depressants; Child; Child, Preschool | 2016 |
The acute exposure of tetrachloro-p-benzoquinone (a.k.a. chloranil) triggers inflammation and neurological dysfunction via Toll-like receptor 4 signaling: The protective role of melatonin preconditioning.
Topics: Animals; Anti-Inflammatory Agents; Chloranil; Disease Models, Animal; Extracellular Signal-Regulated | 2017 |
[Clinical experiences with agomelatine. The inner ear has to be synchronized again].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Controlled Clinical Trials as Topic; Depression | 2010 |
Melatonin protects against Nickel-induced neurotoxicity in vitro by reducing oxidative stress and maintaining mitochondrial function.
Topics: Adenosine Triphosphate; Animals; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Mitochondria | 2010 |
Novel mechanism of action hypothesized for stellate ganglion block related to melatonin.
Topics: Animals; Ganglionic Blockers; Humans; Melatonin; Models, Neurological; Nervous System Diseases; Stel | 2002 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Topics: Adult; Aged; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2003 |
Circadian rhythm disorder in a rare disease: Smith-Magenis syndrome.
Topics: Child; Circadian Rhythm; Developmental Disabilities; Genetic Diseases, Inborn; Humans; Melatonin; Ne | 2006 |
Free radicals and theophylline neurotoxicity : an experimental study.
Topics: alpha-Tocopherol; Aminophylline; Animals; Antioxidants; Arginine; Ascorbic Acid; Dose-Response Relat | 2007 |
Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension.
Topics: Adolescent; Adult; Circadian Rhythm; Female; Humans; Hypotension, Orthostatic; Male; Melatonin; Nerv | 1981 |
Oral melatonin in neurologically disabled children.
Topics: Administration, Oral; Animals; Child; Humans; Melatonin; Nervous System Diseases; Rats; Seizures | 1998 |
Oral melatonin in neurologically disabled children.
Topics: Administration, Oral; Animals; Child; Humans; Melatonin; Nervous System Diseases; Seizures | 1998 |
Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice.
Topics: Animals; Cell Membrane; Cell Nucleus; Kainic Acid; Lipid Peroxidation; Male; Melatonin; Mice; Nervou | 1998 |
Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys.
Topics: Aging; Animals; Circadian Rhythm; Endocrine System Diseases; Female; Macaca mulatta; Melatonin; Nerv | 2001 |
Observations on the cyclic nucleotide concentrations in human cerebrospinal fluid.
Topics: Adult; Child; Child, Preschool; Cyclic AMP; Cyclic GMP; Humans; Infant; Infant, Newborn; Melatonin; | 1976 |
[Relations of melatonin level and insufficiency of T and B immune components in children with acute viral neuroinfections].
Topics: Acute Disease; Adjuvants, Immunologic; Adolescent; Child; Humans; Hydrocortisone; Immunity, Cellular | 1990 |
Measurement of melatonin in blood by radioimmunoassay. Analytical considerations and clinical usefulness.
Topics: Adult; Analysis of Variance; Anticoagulants; Biomarkers; Circadian Rhythm; Female; Humans; Male; Mel | 1990 |